A comparison of the binding sites of antibodies and single-domain antibodies

G. Gordon, Henriette Capel, Bora Guloglu, Eve Richardson, Ryan Stafford, Charlotte M. Deane

Abstract

Antibodies are the largest class of biotherapeutics. However, in recent years, single-domain antibodies have gained traction due to their smaller size and comparable binding affinity. Antibodies (Abs) and single-domain antibodies (sdAbs) differ in the structures of their binding sites: most significantly, single-domain antibodies lack a light chain and so have just three CDR loops. Given this inherent structural difference, it is important to understand whether Abs and sdAbs are distinguishable in how they engage a binding partner and thus, whether they are suited to different types of epitopes. In this study, we use non-redundant sequence and structural datasets to compare the paratopes, epitopes and antigen interactions of Abs and sdAbs. We demonstrate that even though sdAbs have smaller paratopes, they target epitopes of equal size to those targeted by Abs. To achieve this, the paratopes of sdAbs contribute more interactions per residue than the paratopes of Abs. Additionally, we find that conserved framework residues are of increased importance in the paratopes of sdAbs, suggesting that they include non-specific interactions to achieve comparable affinity. Furthermore, the epitopes of sdAbs are only marginally less accessible than those of Abs: we posit that this may be explained by differences in the orientation and compaction of sdAb and Ab CDR-H3 loops. Overall, our results have important implications for the engineering and humanization of sdAbs, as well as the selection of the best modality for targeting a particular epitope.

Introduction

Monoclonal antibodies are the titans of the biotherapeutics world, but their bulk (~150 kDa) makes them expensive to produce and slow to penetrate tissues. Single-domain antibodies (sdAbs, often called nanobodies), derived from camelids, are roughly one-tenth the size (~15 kDa) and offer a promising alternative.

While we know sdAbs lack a light chain and rely on only three CDR loops (compared to six in traditional Abs), it hasn't been clear if this structural simplicity limits the types of targets (epitopes) they can hit. There is a long-standing hypothesis that the long CDR-H3 loops of sdAbs allow them to reach "cryptic" or hidden epitopes that bulky traditional Abs cannot. This paper uses large-scale data to test these assumptions and define the fundamental differences in how these two modalities engage antigens.

Methods

The researchers employed a bioinformatics pipeline to compare paratopes (the antibody's binding residues), epitopes (the antigen's binding residues), and the specific chemical interactions between them.

Binding Definitions

Three metrics were used to define binding:

  1. Distance-based: Residues within 4.5 Å.
  2. SASA-based: Residues that become buried upon binding (Solvent-Accessible Surface Area).
  3. Interaction-based: Identification of specific chemical bonds (vdW, hydrogen bonds, etc.) using the Arpeggio tool.

Datasets

The study utilized large, non-redundant datasets to ensure robust results:

  • Sequence Data: ~1.6 million human VH sequences and ~1.6 million camel VHH sequences from the Observed Antibody Space (OAS) database.
  • Structural Data: 892 Ab-Ag complexes and 345 sdAb-Ag complexes curated from SAbDab and SAbDab-nano.
  • Redundancy Filtering: A 95% sequence identity cut-off was applied to avoid skewing by over-represented antibody families.

Results and Discussion

The Efficiency Paradox and Interaction Density

A key finding is that despite sdAb paratopes being significantly smaller (by about 3.6 residues on average), the epitopes they target are the same size as those targeted by traditional Abs. To compensate for their smaller size, sdAbs are more "efficient" binders, establishing significantly more chemical interactions per paratope residue (a mean increase of 0.19 interactions per residue) than traditional Abs.

Framework Recruitment

Unlike traditional Abs, which rely almost entirely on their CDR loops, sdAbs frequently use "framework" residues (the structural scaffolding) to bind antigens. Framework residues are involved in the paratope in over 10% of sdAb complexes, particularly at positions 66, 52, and 42 (FR2 region).

CDR-H3 Length and Epitope Accessibility

While sdAb CDR-H3 loops are, on average, 1.4 to 1.6 residues longer than those in traditional Abs, they do not always "reach out" further. The study found that sdAbs often pack these long loops down against the antibody domain. This compaction explains why sdAb epitopes are only marginally less accessible than Ab epitopes (a statistically significant but biologically small mean difference of 0.046). This suggests that the "cryptic epitope" advantage of sdAbs may be narrower than previously thought.

Distribution of CDR-H3 loop lengths for sdAbs and Abs.

Conclusion and Future Directions

These findings have major implications for the engineering and humanization of sdAbs. If framework residues are essential for an sdAb's binding, swapping them for human sequences during drug development might destroy the antibody's efficacy. Future research will need to determine how to maintain these "non-CDR" interactions while reducing immunogenicity. The study highlights that structural datasets are inherently biased toward stable complexes, and framework interactions might be "non-specific," contributing to affinity but perhaps not fine-tuned specificity.

Summary updated

Abstract

Antibodies are the largest class of biotherapeutics. However, in recent years, single-domain antibodies have gained traction due to their smaller size and comparable binding affinity. Antibodies (Abs) and single-domain antibodies (sdAbs) differ in the structures of their binding sites: most significantly, single-domain antibodies lack a light chain and so have just three CDR loops. Given this inherent structural difference, it is important to understand whether Abs and sdAbs are distinguishable in how they engage a binding partner and thus, whether they are suited to different types of epitopes. In this study, we use non-redundant sequence and structural datasets to compare the paratopes, epitopes and antigen interactions of Abs and sdAbs. We demonstrate that even though sdAbs have smaller paratopes, they target epitopes of equal size to those targeted by Abs. To achieve this, the paratopes of sdAbs contribute more interactions per residue than the paratopes of Abs. Additionally, we find that conserved framework residues are of increased importance in the paratopes of sdAbs, suggesting that they include non-specific interactions to achieve comparable affinity. Furthermore, the epitopes of sdAbs are only marginally less accessible than those of Abs: we posit that this may be explained by differences in the orientation and compaction of sdAb and Ab CDR-H3 loops. Overall, our results have important implications for the engineering and humanization of sdAbs, as well as the selection of the best modality for targeting a particular epitope.
BibTeX
@inproceedings{gordon2023comparison,
  author = {G. Gordon and Henriette Capel and Bora Guloglu and Eve Richardson and Ryan Stafford and Charlotte M. Deane},
  title = {{A comparison of the binding sites of antibodies and single-domain antibodies}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1231623},
}
Figure